Interview with Yong Taek Chang, Founder, Shin Poong Pharm
Could you please introduce Shinpoong, which you founded in 1962, and mention the main milestones of this unique company in the Korean pharmaceutical industry? I founded Shinpoong in a very…
GL PharmTech (GLPT) has focused on developing improved versions of the currently marketed pharmaceutical products with reduced side effects, greater therapeutic efficacy and better patient compliance using our proprietary drug formulation and delivery technologies since 2002.
We have provided more than 50 pharmaceutical companies in Korea with value-added drug formulations and delivery technologies for generic and improved version of marketed drug.
We are now transitioning from a being a technology transfer-based operation to being a specialty pharmaceutical company capable of developing and delivering new product lines by ourselves from 2010. We are doing this based on intensive investment in various clinical studies of products currently in our pipelines and using our already-established drug delivery platform technologies.
Contact details:
#714 Jungang Induspia V, 137, Sagimakgol-ro,
Jungwon-gu, Seongnam, Gyeonggi-do, Korea
Tel: +82-31-739-5220(ext. 102)
Website: www.glpt.co.kr
Could you please introduce Shinpoong, which you founded in 1962, and mention the main milestones of this unique company in the Korean pharmaceutical industry? I founded Shinpoong in a very…
Novartis’ Head Office in Basel, Switzerland as well as several prior international assignments in Asia and Europe. What do you find as the most interesting particularities of the pharmaceutical sector…
Please introduce the Korean Food and Drug Administration (KFDA) and its main health-related responsibilities within the Korean government… The KFDA’s main duty is to cooperate and support with domestic and…
How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the…
You have a very long track record working with Novo Nordisk in Asia. What is your perspective on the Diabetes explosion that has been taking place in this part of…
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
You are one of the foreign multinational directors with most time in the Korean pharmaceutical industry, since 2003. What is your assessment of the direction the market has taken in…
What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes pharmaceuticals, medical devices, cosmetics,…
Previous to your current position as President of Pfizer Korea since 2004, you had been in the country between 1989 and 1993 as sales and marketing director. How different are…
Please introduce Handok Pharmaceuticals to our readers, and in particular how it has evolved through partnerships with different multinational companies throughout its history. Handok has developed in a very unique…
Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in…
You have been in South Korea for several months, following some time as Merck’s President in Pakistan. In your opinion, what do you find as the most interesting aspects of…
See our Cookie Privacy Policy Here
